Short Interest in Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Drops By 20.4%

Inventiva S.A. Sponsored ADR (NASDAQ:IVA) was the recipient of a significant decrease in short interest in February. As of February 27th, there was short interest totaling 549,755 shares, a decrease of 20.4% from the February 12th total of 690,455 shares. Based on an average daily trading volume, of 324,103 shares, the short-interest ratio is presently 1.7 days. Currently, 0.6% of the shares of the company are sold short. Currently, 0.6% of the shares of the company are sold short. Based on an average daily trading volume, of 324,103 shares, the short-interest ratio is presently 1.7 days.

Analyst Ratings Changes

IVA has been the subject of a number of recent analyst reports. Leerink Partners began coverage on shares of Inventiva in a report on Monday, January 12th. They issued an “outperform” rating and a $12.00 price objective for the company. Guggenheim lowered their target price on shares of Inventiva from $13.00 to $11.00 and set a “buy” rating on the stock in a research note on Tuesday, November 18th. Weiss Ratings restated a “sell (d-)” rating on shares of Inventiva in a research report on Thursday, January 22nd. HC Wainwright set a $24.00 price target on Inventiva and gave the company a “buy” rating in a research note on Wednesday, January 28th. Finally, Barclays started coverage on Inventiva in a report on Tuesday, January 27th. They issued an “overweight” rating and a $18.00 price target for the company. Two analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, Inventiva currently has a consensus rating of “Buy” and an average target price of $17.00.

Inventiva Stock Performance

IVA traded down $0.18 during midday trading on Friday, hitting $5.99. 141,750 shares of the company traded hands, compared to its average volume of 328,033. The business has a 50 day simple moving average of $6.18 and a two-hundred day simple moving average of $5.36. Inventiva has a 52-week low of $2.70 and a 52-week high of $7.98.

Institutional Investors Weigh In On Inventiva

Several institutional investors have recently bought and sold shares of the company. Quadrature Capital Ltd purchased a new stake in Inventiva during the 4th quarter worth approximately $311,000. NewEdge Advisors LLC acquired a new stake in shares of Inventiva in the third quarter worth approximately $116,000. Cerity Partners LLC acquired a new stake in shares of Inventiva in the fourth quarter worth approximately $93,000. XTX Topco Ltd purchased a new stake in shares of Inventiva during the fourth quarter worth approximately $84,000. Finally, Virtu Financial LLC acquired a new position in Inventiva in the 4th quarter valued at $60,000. 19.06% of the stock is currently owned by institutional investors and hedge funds.

About Inventiva

Inventiva (NASDAQ: IVA) is a clinical?stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.